09:01 AM EDT, 08/21/2025 (MT Newswires) -- Gilead Sciences' ( GILD ) Kite unit said Thursday it has agreed to acquire privately-held Interius BioTherapeutics for $350 million in cash.

The transaction is expected to reduce Gilead's 2025 GAAP and non-GAAP EPS by about $0.23 to $0.25, the company said.

Under the deal, Kite will integrate its cell therapy capabilities with Interius's in vivo platform, enabling the generation of CAR T-cells directly inside patients without the need for cell harvesting or preconditioning chemotherapy, the company said.

Interius's team and operations will be integrated into Kite's research team creating a Philadelphia-based center for the development of in vivo therapies, Kite said.

Closing is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

Gilead shares were down 2.8% in recent Thursday premarket activity.